

**A REVIEW ON: CURRENT TRENDS IN FLAVONOID RESEARCH:
MECHANISMS, FUNCTIONS, THERAPEUTIC APPLICATIONS, AND
FUTURE DIRECTIONS IN CHRONIC DISEASE PREVENTION**

**Muhammad Shahnbaj², Dr. Nisha Devi^{*1}, Saurabh², Dr. Jyoti Gupta³, Rajdeep Kaur¹,
Panshul Sharma⁴**

^{*1,1}Associate Professor, IEC University, IEC school of Pharmacy, Baddi, Solan, Himachal Pradesh, 174103, India.

²Research Scholar, IEC University, IEC school of Pharmacy, Baddi, Solan, Himachal Pradesh, 174103, India.

³Professor, IEC University, IEC school of Pharmacy, Baddi, Solan, Himachal Pradesh, 174103, India.

⁴Assistant Professor, IEC University, IEC school of Pharmacy, Baddi, Solan, Himachal Pradesh, 174103, India.

Article Received on 03 March 2026,
Article Revised on 24 March 2026,
Article Published on 01 April 2026,

<https://doi.org/10.5281/zenodo.19327567>

***Corresponding Author**

Dr. Nisha Devi

Associate Professor, IEC University,
IEC School of Pharmacy, Baddi,
Solan, Himachal Pradesh, 174103,
India.



How to cite this Article: Muhammad Shahnbaj², Dr. Nisha Devi^{*1}, Saurabh², Dr. Jyoti Gupta³, Rajdeep Kaur¹, Panshul Sharma⁴ (2026). Review Article on Novel Drug Delivery System. World Journal of Pharmaceutical Research, 15(7), 531-546.

This work is licensed under Creative Commons Attribution 4.0 International license.

ABSTRACT

Flavonoids, a diverse class of polyphenolic compounds ubiquitous in fruits, vegetables, grains, bark, roots, stems, flowers, tea, and wine, have garnered substantial attention for their health-promoting properties. Renowned for antioxidant, anti-inflammatory, antimutagenic, and anticarcinogenic effects, alongside modulation of key cellular enzymes, these natural products underpin nutraceutical, pharmaceutical, medicinal, and cosmetic formulations. The surge in flavonoid research gained momentum following observations of reduced cardiovascular mortality and coronary heart disease (CHD) incidence in populations with high dietary intake. Despite longstanding recognition of plant-derived compounds' broad bioactivity, the precise mechanisms underlying flavonoid actions remain incompletely elucidated. Contemporary research emphasizes isolation, structural identification, physicochemical

characterization, and functional elucidation, with molecular docking and bioinformatics tools increasingly employed to forecast therapeutic potential and guide industrial scale-up. This review synthesizes recent advances in flavonoid research and development, delineating their molecular mechanisms, biological functions, and applications in health maintenance. It further explores predictive modeling for flavonoid-based interventions against chronic diseases and outlines promising avenues for future investigation.

KEYWORDS: Flavonoids, structure, Mechanism, Metabolic disorder.

INTRODUCTION

Flavonoids are naturally occurring polyphenolic compounds widely found in plants and are important plant secondary metabolites. They play key roles in plant growth, pigmentation, and protection against pathogens and ultraviolet radiation (Panche, Diwan and Chandra, 2016; Kumar and Pandey, 2013). Chemically, flavonoids share a C₆–C₃–C₆ structural backbone consisting of two aromatic rings connected by a three-carbon bridge (Beecher, 2003). Based on structural differences, they are classified into groups such as flavonols, flavones, flavanones, flavanols, anthocyanins, and isoflavones (Panche, Diwan and Chandra, 2016). Flavonoids are abundant in plant-based foods like fruits, vegetables, tea, cocoa, and berries, contributing to the health benefits of plant-rich diets (Manach *et al.*, 2004).




Fig. 1: Classification of Flavonoid.

Flavonoid-rich plants have been used for centuries in traditional medicine to treat conditions such as inflammation, infections, digestive disorders, and cardiovascular diseases (Peterson and Dwyer, 1998). Although early medicinal systems did not identify flavonoids specifically,

many therapeutic effects of these plants are now linked to these bioactive compounds (Ross and Kasum, 2002). Scientific interest increased in the late twentieth century due to observations such as the French Paradox, which suggested that red wine consumption may protect against heart disease (Renaud and de Lorgeril, 1992). Red wine contains flavonoids such as anthocyanins and flavonols, which may contribute to this protective effect (Scalbert and Johnson, 2005). Further studies showed that flavonoids support coronary heart disease protection through antioxidant activity, improved endothelial function, and reduced LDL oxidation (Hertog et al., 1993; Hollman and Katan, 1999). Recent advances in analytical chemistry, biotechnology, and molecular biology have greatly expanded flavonoid research (Crozier, Jaganath and Clifford, 2009). Studies focus on identifying new flavonoids and understanding their roles in pathways related to oxidative stress, inflammation, apoptosis, and gene expression (Koutsos et al., 2016). This paper reviews current research and development trends, mechanisms, biological functions, and therapeutic applications of flavonoids (Panche, Diwan and Chandra, 2016). It also highlights technological developments in extraction, purification, and delivery systems that improve flavonoid stability and bioavailability (Dai and Mumper, 2010). Additionally, future directions such as omics technologies, nanotechnology-based delivery systems, and clinical studies are discussed to better understand flavonoid therapeutic potential (Rodriguez-Mateos et al., 2014).

Relevance to Chronic Disease Prevention and Industry Translation

Chronic diseases such as cardiovascular disease, cancer, diabetes, obesity, and neurodegenerative disorders are major global health concerns (Scalbert and Johnson, 2005). These conditions are often linked to oxidative stress, inflammation, and metabolic dysfunction (Spencer, 2010). Flavonoids have gained attention because they can modulate these processes and provide protective health effects (Panche, Diwan and Chandra, 2016). Studies show that flavonoids possess antioxidant, anti-inflammatory, anticancer, antidiabetic, and neuroprotective properties (Li et al., 2016; Nabavi et al., 2015). Due to these benefits, flavonoids are widely used in functional foods, nutraceuticals, and pharmaceutical products, supporting their role in disease prevention and health promotion (Tome-Carneiro and Espín, 2013).

Isolation, Identification, and Characterization of Flavonoids

Isolation of flavonoids from plant materials is essential for studying their chemical composition and biological activities (Stalikas, 2007). Traditional extraction methods mainly

use solvent-based techniques such as maceration, Soxhlet extraction, and reflux extraction with solvents like methanol, ethanol, acetone, or water (Dai and Mumper, 2010). Modern methods such as supercritical fluid extraction (SFE) using carbon dioxide improve efficiency and preserve heat-sensitive flavonoids (Herrero, Cifuentes and Ibáñez, 2006). In recent years, green extraction techniques including ultrasound-assisted, microwave-assisted, pressurized liquid, and enzyme-assisted extraction have been developed (Chemat, Vian and Cravotto, 2012). These methods reduce solvent use, shorten extraction time, and support environmentally sustainable processing (Chemat, Vian and Cravotto, 2012).

Analytical Tools: HPLC-MS, NMR, and FTIR for Structural Elucidation

After extraction, flavonoids must be identified and characterized to determine their chemical structure and biological significance (Markham, 1982). Techniques such as high-performance liquid chromatography coupled with mass spectrometry (HPLC–MS) are widely used to separate flavonoids and identify them based on molecular weight and fragmentation patterns (Cuyckens and Claeys, 2004). Nuclear Magnetic Resonance (NMR) spectroscopy helps determine detailed molecular structures, including atom arrangement and functional groups (Agrawal, 1989). Fourier-transform infrared spectroscopy (FTIR) is used to detect characteristic chemical bonds present in flavonoid molecules (Stuart, 2004). Together, these analytical techniques allow accurate qualitative and quantitative analysis of flavonoids in plant extracts (Silverstein, Webster and Kiemle, 2014).

Challenges: Bioavailability, Stability, and Standardization in Complex Matrices

Despite progress in flavonoid research, several challenges remain in their study and application. One major issue is low bioavailability, as many flavonoids have poor solubility, rapid metabolism, and limited absorption in the intestine (Manach et al., 2005; D'Archivio et al., 2010). Researchers are exploring solutions such as nanoformulations, encapsulation, and chemical modification to improve their delivery (Costa et al., 2019). Another challenge is stability, since flavonoids can degrade due to light, temperature, oxygen, and pH changes during processing and storage (Friedman and Jürgens, 2000; Xiao and Hogger, 2015). Standardization is also difficult because flavonoid content varies with plant species, location, and cultivation conditions (Crozier, Jaganath and Clifford, 2009). Therefore, reliable analytical methods and quality control are needed for consistency in flavonoid-based products (Stalikas, 2007).

MOLECULAR MECHANISMS OF ACTION

Antioxidant Pathways: ROS Scavenging, Nrf2 Activation, and Enzyme Inhibition

Flavonoids show strong antioxidant activity by neutralizing reactive oxygen species (ROS) and reducing oxidative stress linked to chronic diseases (Rice-Evans, 2001). Their hydroxyl groups enable them to scavenge free radicals and prevent lipid peroxidation (Kandaswami and Middleton, 1994). Flavonoids also activate the Nrf2 signaling pathway, which increases the production of antioxidant enzymes (Kobayashi and Yamamoto, 2005). These enzymes include superoxide dismutase, catalase, and glutathione peroxidase (Koutsos et al., 2016). Additionally, flavonoids inhibit enzymes like xanthine oxidase, helping protect cells from oxidative damage (Ghasemzadeh and Jaafar, 2012).

Anti-inflammatory Effects: NF- κ B Suppression and Cytokine Modulation

Flavonoids exhibit strong anti-inflammatory effects, which help reduce the risk of chronic diseases such as cardiovascular disorders, diabetes, and cancer (Nabavi et al., 2015). They suppress the activation of NF- κ B, a key transcription factor that controls pro-inflammatory gene expression (Aggarwal, 2006). This inhibition reduces inflammatory mediators like TNF- α , IL-1 β , and IL-6 (Serafini et al., 2010). Flavonoids also regulate cytokine production and inhibit enzymes such as cyclooxygenase (COX) and lipoxygenase (LOX) (Li et al., 2016). Through these mechanisms, they help control inflammation and protect tissues from chronic inflammatory damage (Nabavi et al., 2015).

Anticarcinogenic and Antimutagenic Roles

Flavonoids have significant anticancer and antimutagenic potential and may help prevent tumor development (Ren et al., 2003). They induce apoptosis (programmed cell death) in abnormal cells and inhibit uncontrolled cell growth (Batra and Sharma, 2013). Flavonoids also regulate signaling pathways that control the cell cycle, causing arrest at phases such as G1 or G2/M (Khan and Mukhtar, 2013). In addition, they enhance DNA repair mechanisms and protect genetic material from oxidative and mutagenic damage (Hardy and Tollefsbol, 2011).

BIOLOGICAL FUNCTIONS AND HEALTH APPLICATIONS

Flavonoids support cardiovascular health through several protective mechanisms. They promote vasodilation by increasing nitric oxide production, which improves blood flow and helps regulate blood pressure (Spencer, 2010; Moreno and Blumberg, 2018). These compounds also help reduce low-density lipoprotein (LDL) oxidation and improve the

balance between LDL and high-density lipoprotein (HDL) cholesterol (Scalbert and Johnson, 2005). In addition, flavonoids decrease inflammation and oxidative stress in blood vessels (Rice-Evans, 2001). This contributes to plaque stabilization and reduced risk of atherosclerosis and coronary heart disease (Hertog et al., 1993; Spencer, 2010).

Anticancer Potential

Flavonoids have shown promising anticancer and chemopreventive effects in numerous experimental and epidemiological studies. They inhibit tumor growth by regulating cell proliferation and inducing apoptosis in cancer cells (Ren et al., 2003; Batra and Sharma, 2013). Research indicates protective effects in colorectal, breast, and prostate cancer models, where flavonoids can interfere with signaling pathways involved in tumor progression (He and Sun, 2016; Khan et al., 2023). Flavonoids also suppress angiogenesis and oxidative DNA damage, which are key processes in tumor development (Kabała-Dzik et al., 2019). These findings highlight the potential role of flavonoids as chemopreventive agents and supportive therapies in cancer management (Bars-Cortina et al., 2022).

Metabolic Disorders

Flavonoids are widely studied for their role in managing metabolic disorders such as diabetes and obesity. These compounds improve glycemic control by enhancing insulin sensitivity and glucose metabolism (Ross and Kasum, 2002). Some flavonoids interact with peroxisome proliferator-activated receptor gamma (PPAR γ), a key regulator of lipid metabolism and adipocyte differentiation (Staels and Fruchart, 2005). Activation of this receptor helps regulate fat storage and reduce inflammation in adipose tissue (Griffin et al., 2019). These effects support the potential of flavonoids in preventing metabolic syndrome and type 2 diabetes (American Diabetes Association, 2022).

Other Applications

Flavonoids also demonstrate a wide range of biological activities beyond metabolic and cardiovascular health. They provide neuroprotective effects by reducing oxidative stress and modulating neuronal signaling pathways in the brain (Spencer, 2008). These properties may help prevent neurodegenerative diseases such as Alzheimer's and Parkinson's disease (Spencer, 2008). Flavonoids also possess antimicrobial activity against various bacteria, fungi, and viruses by disrupting microbial membranes and inhibiting essential enzymes (Cushnie and Lamb, 2011). In cosmetic and dermatological applications, flavonoids are used

for skin protection, UV defense, and anti-aging effects due to their antioxidant and anti-inflammatory properties (Scalbert and Johnson, 2005).

Nutraceutical and Pharmaceutical Formulations: Nanoencapsulation for Enhanced Delivery

Many flavonoids have poor solubility and limited bioavailability, which restrict their therapeutic applications (Rodriguez-Mateos *et al.*, 2014). To overcome these limitations, advanced delivery systems such as nanoencapsulation are being developed (Costa *et al.*, 2019). This technique incorporates flavonoids into nanoparticles, liposomes, or polymer carriers, which improves stability, absorption, and controlled release (Tome-Carneiro and Espín, 2013). These delivery systems enhance the bioavailability and therapeutic effectiveness of flavonoids and support their use in functional foods, nutraceuticals, and pharmaceutical formulations (Costa *et al.*, 2019).

PREDICTIVE TOOLS: MOLECULAR DOCKING AND BIOINFORMATICS

Computational Approaches: Docking Simulations for Flavonoid–Protein Interactions

Computational methods have become important tools in modern flavonoid research, allowing scientists to predict molecular interactions and biological activities before conducting laboratory experiments. One widely used technique is molecular docking, which simulates the binding of flavonoid molecules to specific target proteins involved in disease pathways (Fujisaki *et al.*, 2018). Docking software such as AutoDock helps researchers analyze binding affinity, orientation, and stability of flavonoid–protein complexes. Through these simulations, scientists can identify potential targets such as enzymes, receptors, or signaling proteins that flavonoids may regulate (Khan *et al.*, 2023). This computational approach accelerates the screening of large numbers of flavonoid compounds and helps prioritize candidates for further experimental validation in drug discovery and therapeutic development (Fujisaki *et al.*, 2018).

IN SILICO PREDICTIONS: ADMET PROFILING AND QSAR MODELS FOR BIOACTIVITY

In addition to docking studies, *in silico* predictive models are widely used to evaluate the pharmacological potential of flavonoids. ADMET profiling, which evaluates absorption, distribution, metabolism, excretion, and toxicity, helps estimate how flavonoid compounds behave in the human body (Rodriguez-Mateos *et al.*, 2014). These predictions assist researchers in identifying compounds with favorable pharmacokinetic and safety profiles

before expensive laboratory testing. Another important computational method is quantitative structure–activity relationship (QSAR) modeling, which examines the relationship between chemical structure and biological activity (Khan et al., 2023). QSAR models use statistical and machine-learning approaches to predict antioxidant, anti-inflammatory, or anticancer properties based on molecular descriptors. Together, these bioinformatics tools enhance the efficiency of flavonoid research and guide experimental design in drug discovery and nutraceutical development (Fujisaki et al., 2018).

FLAVONOIDS AS POTENTIAL DRUGS FOR CHRONIC DISEASES

Evidence from Epidemiology and RCTs: Meta-Analyses on CVD, Diabetes, and Cancer Risk Reduction

Epidemiological studies and randomized controlled trials provide substantial evidence for the role of flavonoids in chronic disease prevention. Meta-analyses indicate that flavonoid-rich diets are associated with a lower risk of cardiovascular disease, diabetes, and certain cancers (Grosso et al., 2017; Wang et al., 2014). These compounds improve vascular function and reduce oxidative stress, which are important mechanisms in disease prevention (Spencer, 2010). Clinical studies also report improvements in blood pressure, lipid profiles, and insulin sensitivity among individuals consuming flavonoid-rich foods (Huxley and Neil, 2003). However, further long-term clinical trials are necessary to confirm their therapeutic effectiveness and establish optimal dosage ranges.

Drug Development Pipeline: Semi-Synthetic Derivatives and Clinical Trial Status

Flavonoids are being explored in drug development because of their diverse biological activities and relatively low toxicity (Ren et al., 2003). Researchers are developing semi-synthetic derivatives to improve potency, stability, and pharmacokinetic properties (Mukherjee, 2019). For example, compounds derived from quercetin are being investigated for enhanced anticancer and anti-inflammatory activities (Zhang et al., 2024). Several flavonoid-based compounds have entered preclinical and early clinical trials, highlighting their potential as templates for the development of new therapeutic agents (Shriyan et al., 2025).

Regulatory Considerations: GRAS Status, Safety Profiles, and Toxicity Thresholds

Regulatory agencies evaluate flavonoids to ensure their safety, quality, and efficacy before approval for human use. Many dietary flavonoids are classified as Generally Recognized as Safe (GRAS) when consumed at normal dietary levels (Ross and Kasum, 2002).

Toxicological studies indicate that most flavonoids have low toxicity and favorable safety profiles, although very high doses may interact with drug-metabolizing enzymes or medications (Williamson and Manach, 2005). Therefore, regulatory frameworks require standardized testing, dosage guidelines, and proper labeling to ensure safe consumption of flavonoid-based products.

Barriers: Poor Solubility, Rapid Metabolism, and Emerging Solutions

Despite their therapeutic potential, several barriers limit the clinical application of flavonoids. Many flavonoids exhibit poor aqueous solubility, low intestinal absorption, and rapid metabolism, which reduce their bioavailability (Manach et al., 2005). To overcome these challenges, researchers are developing nanocarriers, liposomes, and polymer-based nanoparticles that improve drug delivery and stability (Costa et al., 2019). Additionally, strategies such as chemical modification, prodrug design, and structural optimization are being explored to enhance pharmacokinetics and therapeutic efficacy (Mukherjee, 2019).

FUTURE RESEARCH DIRECTIONS

Emerging Frontiers: Gut Microbiome Interactions and Personalized Nutrition via Pharmacogenomics

Future flavonoid research increasingly focuses on the interaction between flavonoids and the gut microbiome, which plays a crucial role in metabolizing these compounds and influencing their biological effects (Crozier, Jaganath and Clifford, 2009). Gut microorganisms can convert flavonoids into bioactive metabolites that may enhance or modify their health benefits (Williamson and Manach, 2005). Additionally, advances in pharmacogenomics and personalized nutrition are helping researchers understand how genetic differences influence individual responses to flavonoid intake (Rodriguez-Mateos et al., 2014). This knowledge may allow the development of personalized dietary interventions for chronic disease prevention.

Technological Synergies: CRISPR for Flavonoid Biosynthesis and Organoids for Efficacy Testing

Innovative technologies are opening new avenues for flavonoid research and production. CRISPR-based gene editing is being explored to enhance flavonoid biosynthesis in plants by modifying genes involved in flavonoid metabolic pathways (Crozier, Jaganath and Clifford, 2009). This approach could lead to crops with higher flavonoid content and improved nutritional value. Additionally, advanced biological models such as organoids, which mimic

human tissues under laboratory conditions, are being used to evaluate flavonoid efficacy and toxicity more accurately (Khan et al., 2023). These technologies provide more reliable experimental models and may accelerate drug discovery and functional food development.

Sustainability: Plant Breeding and Microbial Engineering for Scalable Production

As demand for natural bioactive compounds increases, sustainable production of flavonoids has become a major research priority. Plant breeding programs aim to develop crop varieties with enhanced flavonoid content and improved resistance to environmental stress (Beecher, 2003). In addition, microbial engineering using bacteria or yeast is emerging as an efficient approach for large-scale flavonoid production through metabolic engineering and synthetic biology (Crozier, Jaganath and Clifford, 2009). These methods provide environmentally friendly and scalable solutions for pharmaceutical and nutraceutical industries.

Translational Gaps: Long-Term Human Trials, Combination Therapies, and Global Health Equity

Despite promising laboratory findings, several translational challenges remain in flavonoid research. One major limitation is the lack of long-term human clinical trials confirming their safety and therapeutic effectiveness (Rodriguez-Mateos et al., 2014). Researchers are also exploring combination therapies, where flavonoids may enhance the effects of conventional drugs (Khan et al., 2023). Another important issue is global health equity, as access to flavonoid-rich foods and supplements varies widely among populations (Scalbert and Johnson, 2005). Addressing these challenges will require collaborative research, well-designed clinical studies, and supportive health policies.

CONCLUSION

Flavonoids represent a diverse group of plant-derived polyphenolic compounds with significant potential for promoting human health and preventing chronic diseases (Panche, Diwan and Chandra, 2016). Extensive research demonstrates that flavonoids exhibit multiple biological activities, including antioxidant, anti-inflammatory, anticancer, antidiabetic, and neuroprotective effects (Li et al., 2016; Nabavi et al., 2015). These activities arise from their ability to modulate key molecular pathways, regulate enzyme activity, and protect cells from oxidative and inflammatory damage (Rice-Evans, 2001).

Recent advances in analytical chemistry, biotechnology, computational modeling, and nanotechnology have expanded flavonoid research and applications (Rodriguez-Mateos et al.,

2014). Techniques such as molecular docking, bioinformatics analysis, and nanoencapsulation are helping researchers identify therapeutic targets, improve bioavailability, and develop more effective flavonoid-based formulations (Costa et al., 2019). These innovations support the translation of flavonoid research into practical applications in the pharmaceutical, nutraceutical, and functional food industries.

However, several challenges remain, including limited bioavailability, variability in plant sources, and the need for standardized extraction and quality control methods (Manach et al., 2005). Furthermore, additional long-term human clinical trials are necessary to confirm the safety and therapeutic efficacy of flavonoids in chronic disease prevention and treatment.

Future research should integrate omics technologies, CRISPR-based biosynthesis, microbiome studies, and advanced biological models to better understand flavonoid mechanisms and improve large-scale production (Crozier, Jaganath and Clifford, 2009). Continued interdisciplinary research and technological innovation will be essential to fully realize the potential of flavonoids in global health promotion and preventive medicine.

REFERENCES

1. Panche, A. N., Diwan, A. D., & Chandra, S. R. (2016). Flavonoids: An overview. *Journal of Nutritional Science*, 5: e47.
2. Panche et al., 2016; Kumar, S., & Pandey, A. K. (2013). Chemistry and biological activities of flavonoids: An overview. *The Scientific World Journal*, 2013; 162750.
3. Panche et al., 2016; Kumar & Pandey, 2013.
4. Manach, C., Scalbert, A., Morand, C., Rémésy, C., & Jiménez, L. Polyphenols: Food sources and bioavailability. *The American Journal of Clinical Nutrition*, 2004; 79(5): 727–747.
5. Albert Szent-Györgyi (1938). Observations on the physiological activity of flavonoids (vitamin P). *Nature*.
6. Serge Renaud & Michel de Lorgeril. Wine, alcohol, platelets, and the French Paradox. *The Lancet*, 1992; 339: 1523–1526.
7. Hertog, M. G. L., et al. Dietary antioxidant flavonoids and risk of Coronary Heart Disease: The Zutphen Elderly Study. *The Lancet*, 1993; 342: 1007–1011.
8. Hollman, P. C. H., & Katan, M. B. (1999). Dietary flavonoids: Intake, health effects, and bioavailability. *Food and Chemical Toxicology*.

9. Panche, A. N., Diwan, A. D., & Chandra, S. R. (2016). Flavonoids: An overview. *Journal of Nutritional Science*, 5: e47.
10. Kumar, S., & Pandey, A. K. (2013). Chemistry and biological activities of flavonoids. *The Scientific World Journal*, 2013; 162750.
11. Hollman, P. C. H., Cassidy, A., Comte, B., et al. (2010). The biological relevance of dietary flavonoids. *Journal of Nutrition*, 141(5): 989S–1009S.
12. Beecher, G. R. (2003). Overview of dietary flavonoids: Nomenclature, occurrence and intake. *Journal of Nutrition*, 133(10): 3248S–3254S.
13. Dai, J., & Mumper, R. J. (2010). Plant phenolics: Extraction, analysis and antioxidant properties. *Molecules*, 15: 7313–7352.
14. Herrero, M., Cifuentes, A., & Ibáñez, E. (2006). Sub- and supercritical fluid extraction of functional ingredients from natural sources. *Food Chemistry*, 98: 136–148.
15. Chemat, F., Vian, M. A., & Cravotto, G. (2012). Green extraction of natural products: Concept and principles. *International Journal of Molecular Sciences*, 13: 8615–8627.
16. Dai, J., & Mumper, R. J. (2010). Plant phenolics: Extraction, analysis and their antioxidant and anticancer properties. *Molecules*, 15(10): 7313–7352.
17. Cuyckens, F., & Claeys, M. (2004). Mass spectrometry in the structural analysis of flavonoids. *Journal of Mass Spectrometry*, 39: 1–15.
18. Markham, K. R. (1982). *Techniques of Flavonoid Identification*. Academic Press.
19. Agrawal, P. K. (1989). *Carbon-13 NMR of Flavonoids*. Elsevier.
20. Stuart, B. (2004). *Infrared Spectroscopy: Fundamentals and Applications*. Wiley.
21. Silverstein, R. M., Webster, F. X., & Kiemle, D. (2014). *Spectrometric Identification of Organic Compounds*. Wiley.
22. Manach, C., et al. (2005). Polyphenols: food sources and bioavailability. *American Journal of Clinical Nutrition*, 81(1): 230S–242S.
23. D'Archivio, M., et al. (2010). Bioavailability of the polyphenols: status and controversies. *International Journal of Molecular Sciences*, 11(4): 1321–1342
24. Friedman, M., & Jürgens, H. S. (2000). Effect of pH on the stability of plant phenolic compounds. *Journal of Agricultural and Food Chemistry*, 48(6): 2101–2110.
25. Xiao, J., & Hogger, P. (2015). Stability of dietary polyphenols under the cell culture conditions. *Journal of Agricultural and Food Chemistry*, 63(5): 1545–1552.
26. Crozier, A., Jaganath, I. B., & Clifford, M. N. (2009). Dietary phenolics: chemistry, bioavailability and effects on health. *Natural Product Reports*, 26(8): 1001–1043.

27. Stalikas, C. D. (2007). Extraction, separation, and detection methods for phenolic acids and flavonoids. *Journal of Separation Science*, 30(18): 3268–3295.
28. Behzad Ghasemzadeh, Sajad Jaafar Hawa. Flavonoid compounds and their antioxidant activity in plants. *Molecules*. 2012; 17(3): 2473-2492.
29. Akira Kobayashi, Masayuki Yamamoto. Molecular mechanisms activating the Nrf2-Keap1 pathway of antioxidant defense. *Annual Review of Pharmacology and Toxicology*. 2005; 45: 273-296.
30. Panayiotis A. Koutsos et al. Dietary flavonoids and their role in enzyme inhibition and antioxidant defense. *Journal of Nutritional Biochemistry*. 2016; 33: 1-13.
31. Behzad Nabavi, Seyed Mohammad Nabavi, et al. (2015). Anti-inflammatory effects of flavonoids: Mechanisms and therapeutic potential. *Critical Reviews in Food Science and Nutrition*, 55(5): 603-613.
32. Ilaria Serafini, et al. (2010). Flavonoids as anti-inflammatory agents. *Molecular Nutrition & Food Research*, 54(4): 532-543.
33. Catherine A. Rice-Evans (2001). Flavonoid antioxidants. *Free Radical Biology and Medicine*, 20(7): 933-956.
34. Bharat B. Aggarwal (2006). Nuclear factor- κ B: The enemy within. *Cancer Cell*, 9(2): 81-87.
35. Panche, A. N., Diwan, A. D., & Chandra, S. R. (2016). Flavonoids: an overview. *Journal of Nutritional Science*, 5, e47.
36. Beecher, G. R. (2003). Overview of dietary flavonoids: nomenclature, occurrence and intake. *Journal of Nutrition*, 133(10): 3248S–3254S.
37. Kandaswami, C., & Middleton, E. (1994). Free radical scavenging and antioxidant activity of plant flavonoids. *Advances in Experimental Medicine and Biology*, 366: 351–376.
38. Ren, W., Qiao, Z., Wang, H., Zhu, L., & Zhang, L. (2003). Flavonoids: promising anticancer agents. *Medicinal Research Reviews*, 23(4): 519–534.
39. Batra, P., & Sharma, A. K. (2013). Anti-cancer potential of flavonoids: recent trends and future perspectives. *3 Biotech.*, 3(6): 439–459.
40. Panche, A. N., Diwan, A. D., & Chandra, S. R. (2016). Flavonoids: An overview. *Journal of Nutritional Science*, 5, e47.
41. Kumar, S., & Pandey, A. K. (2013). Chemistry and biological activities of flavonoids: An overview. *The Scientific World Journal*, 2013: 162750.

42. Batra, P., & Sharma, A. K. (2013). Anti-cancer potential of flavonoids: Recent trends and future perspectives. *3 Biotech*, 3(6): 439–459.
43. Rodriguez-Mateos, A., et al. (2014). Bioavailability and health effects of flavonoids. *Current Medicinal Chemistry*, 21(1): 31–46.
44. Li, Y., Yao, J., Han, C., et al. (2016). Quercetin, inflammation and immunity. *Nutrients*, 8(3): 167.
45. Khan N, Mukhtar H. (2013). Modulation of signaling pathways in prostate cancer by green tea polyphenols. *Biochemical Pharmacology*, 85(5): 667–672.
46. Hardy T. M., Tollefsbol T. O. (2011). Epigenetic diet: impact on the epigenome and cancer. *Epigenomics*, 3(4): 503–518.
47. Li Y, Yao J., Han C., et al. (2016). Quercetin, inflammation and immunity. *Nutrients*, 8(3): 167.
48. Ross J. A., Kasum C. M. (2002). Dietary flavonoids: bioavailability, metabolic effects, and safety. *Annual Review of Nutrition*, 22: 19–34.
49. Manuel J. Moreno, Jeffrey B. Blumberg (2018). Flavonoids and cardiovascular health: A review. *Nutrients*, 10(6): 1–21.
50. Andrew J. Scalbert, Ian T. Johnson (2005). Dietary polyphenols and prevention of diseases. *Critical Reviews in Food Science and Nutrition*, 45(4): 287–306.
51. Jeremy P. E. Spencer (2010). The impact of flavonoids on cardiovascular health. *Proceedings of the Nutrition Society*, 69(2): 244–252.
52. Panche, A. N., et al. “Flavonoids: An overview.” *Cancer Communications*, 2017.
53. Bars-Cortina, D., et al. “Chemopreventive effects of anthocyanins on colorectal and breast cancer.” *Seminars in Cancer Biology*, 2022.
54. He, X., & Sun, L. “Dietary intake of flavonoid subclasses and risk of colorectal cancer.” *Oncotarget*, 2016.
55. Kabała-Dzik, A., et al. “Flavonoids as cancer chemopreventive agents.” *Nutrients*, 2019.
56. Khan, H., et al. “Flavonoids target different molecules in cancer cells.” *Cancer Cell International*, 2023.
57. “PPAR- γ : Adipogenic regulator and thiazolidinedione receptor.” *Diabetes*, 1998.
58. Bart Staels & Fruchart, J.C. “Therapeutic roles of peroxisome proliferator-activated receptor agonists.” *Diabetes*, 2005.
59. Ian J. Griffin et al. “Flavonoids as modulators of PPAR γ and metabolic diseases.” *Nutrients*, 2019.

60. American Diabetes Association. Standards of Medical Care in Diabetes. Diabetes Care, 2022.
61. Spencer, J. P. E. (2008). Flavonoids: modulators of brain function? *British Journal of Nutrition*, 99(E-S1), ES60–ES77. <https://doi.org/10.1017/S0007114508965776>
62. Cushnie, T. P. T., & Lamb, A. J. (2011). Recent advances in understanding the antibacterial properties of flavonoids. *International Journal of Antimicrobial Agents*, 38(2): 99–107.
63. et al. (2017). Nanoencapsulation of bioactive compounds: Principles and applications in nutraceutical delivery systems. *Food Hydrocolloids*, 63: 543–552.
64. Francisco A. Tome-Carneiro & Juan Carlos Espin (2013). Nutraceutical and therapeutic applications of flavonoid nanoformulations. *Journal of Agricultural and Food Chemistry*, 61(36): 8776–8787.
65. Eunice Costa et al. (2019). Flavonoid delivery systems in nutraceutical and pharmaceutical applications. *Nanomaterials*, 9(5): 1–20.
66. Wang X. et al. Flavonoid intake and mortality from cardiovascular disease and all causes: A meta-analysis of prospective cohort studies. *Nutrients*.
67. Grosso G. et al. Dietary flavonoid intake and risk of mortality from all causes and cardiovascular disease: systematic review and meta-analysis. *Mol. Nutr. Food Res.*,
68. Huxley R.R., Neil H.A. Flavonoids and cardiovascular risk: meta-analysis of randomized controlled trials. *Am J Clin. Nutr.*
69. Zamora-Ros R. et al. Dietary flavonoids intake and risk of type 2 diabetes: meta-analysis of prospective cohort studies. *Clin. Nutr.*
70. Fujisaki K. et al. Network pharmacology framework characterizes polypharmacological properties of dietary flavonoids.
71. Ferry DR et al. Phase I clinical trial of quercetin: pharmacokinetics and tyrosine kinase inhibition. *Clin Cancer Res*. 1996.
72. Mukherjee A. Semisynthetic quercetin derivatives with potent antitumor activity. *ACS Omega*. 2019.
73. Zhang W. et al. Design and synthesis of quinoline-containing quercetin derivatives with antitumor activity. *Molecules*. 2024.
74. Shriyan CS et al. Advances in semi-synthetic derivatives of quercetin and pharmacological potential. *J. Pharmacognosy & Phytochemistry*. 2025.
75. D'Archivio, M., et al. (2010). Polyphenols, dietary sources and bioavailability. *Annali dell'Istituto Superiore di Sanità*, 46(4): 348–361.

76. Manach, C., et al. (2004). Polyphenols: Food sources and bioavailability. *The American Journal of Clinical Nutrition*, 79(5): 727–747.
77. Peterson, J., & Dwyer, J. (1998). Flavonoids: Dietary occurrence and biochemical activity. *Nutrition Research*, 18(12): 1995–2018.
78. Williamson, G., & Manach, C. (2005). Bioavailability and bioefficacy of polyphenols in humans. *The American Journal of Clinical Nutrition*, 81(1): 243S–255S.